Jay R. Luly, President and CEO at ENANTA PHARMACEUTICALS INC (ENTA), sold 55,824 shares at $45.31 ($2.5M) on 2023-03-13, disclosed to the SEC on 2023-03-14.
Seasonal sale ($2.5M) by President and CEO — this insider has traded ENTA in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.81 | 10,697 | $479K | 19.0% |
| 2 | $44.81 | 10,697 | $479K | 19.0% |
| 3 | $45.31 | 15,649 | $709K | 28.1% |
| 4 | $45.31 | 15,649 | $709K | 28.1% |
| 5 | $46.13 | 1,566 | $72K | 2.9% |
| 6 | $46.13 | 1,566 |
| $72K |
| 2.9% |
| Total | $45.16 avg | 55,824 | $2.5M | 100% |
| Filing → |
| ENTA | SELL | 2024-12-10 | $41K | — | Filing → |
| ENTA | SELL | 2023-12-06 | $139K | — | Filing → |
| ENTA | SELL | 2022-12-16 | $2.3M | — | Filing → |